NASDAQ:CBIO
Delisted
Catalyst Biosciences Stock News
$0.511
+0 (+0%)
At Close: Dec 14, 2023
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
08:00am, Wednesday, 20'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and All
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
08:00am, Friday, 15'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hos
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
08:00am, Monday, 07'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
04:02pm, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic com
Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
07:18pm, Friday, 13'th Nov 2020
Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered i
Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference
09:00am, Thursday, 05'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
08:00am, Thursday, 05'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2
Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference
08:00am, Tuesday, 03'rd Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Clinton M
National Hemophilia Foundation Revises Treatment Guidelines for Factor 1 Deficiency to Include Octapharma’s fibryga®
12:00am, Wednesday, 07'th Oct 2020
The National Hemophilia Foundation has revised its treatment recommendations for congenital fibrinogen (Factor 1) deficiency to include fibryga®.
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
12:00pm, Thursday, 06'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2020
Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress
12:00pm, Monday, 13'th Jul 2020
Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels Data confirm Phase 3 study design to treat acute bleeding events in.
Does Catalyst Biosciences' (NASDAQ:CBIO) Share Price Gain of 34% Match Its Business Performance?
01:48pm, Thursday, 09'th Jul 2020
It might be of some concern to shareholders to see the Catalyst Biosciences, Inc. (NASDAQ:CBIO) share price down 24...
Hedge Funds Still Very Bullish On Catalyst Biosciences Inc (CBIO)
01:28am, Wednesday, 08'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Two Sigma Advisers LP Increases Stock Position in Catalyst Biosciences Inc (NASDAQ:CBIO)
04:50am, Monday, 06'th Jul 2020
Two Sigma Advisers LP raised its holdings in Catalyst Biosciences Inc (NASDAQ:CBIO) by 39.2% during the 1st quarter, Holdings Channel reports. The firm owned 193,100 shares of the biopharmaceutical co
